Gain Therapeutics, INC

Gain Therapeutics announced its cash and cash equivalents are projected to fund operations into Q2 2027, with key clinical trial milestones expected in late 2026.

Gain Therapeutics announced the FDA has authorized its Investigational New Drug application for GT-02287, paving the way for Phase 2 clinical development in Parkinson's disease.

Gain Therapeutics shareholders re-elected seven directors and ratified the appointment of Ernst & Young AG as the company's independent auditor.

Gain Therapeutics presented interim clinical and biomarker data from its Phase 1b study of GT-02287 for Parkinson's disease, showing promising tolerability and potential benefits.

Gain Therapeutics reports Q1 2026 financial results, highlighting progress in its Parkinson's disease candidate GT-02287 and a new lead compound GT-04686.

Gain Therapeutics announced its 2025 financial results and significant clinical and preclinical progress for its Parkinson's disease drug candidates, GT-02287 and GT-04686.

Gain Therapeutics reports increased operating expenses in Q1 2026, with a net loss of $5.6 million, and highlights substantial doubt about its ability to continue as a going concern.

Gain Therapeutics reported a net loss of $15.6 million for the nine months ended September 30, 2025, while extending its Phase 1b Parkinson's disease study due to positive participant retention.

Gain Therapeutics reported a reduced net loss in Q2 2025, driven by lower operating expenses, but faces substantial doubt about its ability to continue as a going concern beyond Q1 2026 despite recent capital raises.

Gain Therapeutics reports a net loss of $4.53 million for Q1 2025, with ongoing efforts to advance its clinical programs and secure additional funding amid going concern uncertainties.

Gain Therapeutics' Q3 2024 report highlights ongoing clinical trials and financial challenges, including a going concern warning.

Gain Therapeutics reports its Q2 2024 financial results, highlighting ongoing losses and raising substantial doubt about its ability to continue as a going concern.

Gain Therapeutics reports positive Phase 1b Parkinson's trial data for GT-02287 but acknowledges substantial doubt about its ability to continue as a going concern beyond Q1 2027.

Gain Therapeutics' 10-K filing reveals ongoing efforts in Parkinson's disease treatment development and financial strategies to maintain operations.

Gain Therapeutics' 10-K filing outlines the company's stock structure, ongoing clinical trials, and future strategic directions, while also highlighting financial risks and regulatory challenges.

Dov A Goldstein, a Director of Gain Therapeutics, Inc., received 25,000 shares of common stock on July 15, 2026.

Claude Nicaise, a Director of Gain Therapeutics, Inc., received 25,000 shares of common stock on July 15, 2026.

Khalid Islam, a Director of Gain Therapeutics, Inc., received 25,000 shares of common stock on July 15, 2026.

Gwen A Melincoff, a Director of Gain Therapeutics, Inc., received 25,000 shares of common stock on July 15, 2026.

Jeffrey Scott Riley, a Director of Gain Therapeutics, Inc., received 25,000 shares of common stock on July 15, 2026.

Hans Peter Hasler, a Director of Gain Therapeutics, Inc., received 25,000 shares of common stock on July 15, 2026.

Gain Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 24, 2026, to elect directors and ratify auditor selection.

Gain Therapeutics will hold its annual stockholders meeting on June 24, 2025, to vote on director elections, auditor ratification, an increase in authorized shares, and adjournment options.

Gain Therapeutics is holding its 2025 Annual Meeting of Stockholders to elect directors, ratify the selection of its accounting firm, and approve an increase in authorized common stock.

Gain Therapeutics announces its 2024 Annual Meeting of Stockholders to be held on June 24, 2024, with key proposals including the election of directors and ratification of the company's independent auditor.

Gain Therapeutics announces its 2024 Annual Meeting of Stockholders to be held on June 24, 2024, to elect directors and ratify the selection of its independent accounting firm.